Northeast Financial Consultants’s Guardant Health GH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-8,646
Closed -$203K – 308
2023
Q1
$203K Hold
8,646
– – 0.01% 298
2022
Q4
$235K Hold
8,646
– – 0.02% 275
2022
Q3
$465K Hold
8,646
– – 0.03% 199
2022
Q2
$349K Hold
8,646
– – 0.02% 239
2022
Q1
$573K Hold
8,646
– – 0.03% 209
2021
Q4
$865K Buy
8,646
+1,698
+24% +$176K 0.05% 169
2021
Q3
$869K Buy
6,948
+1,441
+26% +$171K 0.06% 172
2021
Q2
$684K Hold
5,507
– – 0.05% 187
2021
Q1
$841K Hold
5,507
– – 0.06% 157
2020
Q4
$710K Hold
5,507
– – 0.06% 158
2020
Q3
$616K Hold
5,507
– – 0.06% 155
2020
Q2
$447K Buy
5,507
+252
+5% +$20.3K 0.04% 182
2020
Q1
$366K Buy
+5,255
New +$403K 0.04% 185

Other funds holding GH

Northeast Financial Consultants's GH Position: Q2 2023 in Review

Northeast Financial Consultants sold out of Guardant Health (GH) in Q2 2023, closing a stake of 8,646 shares — an estimated $203K sold.

Northeast Financial Consultants first reported a position in GH in Q1 2020 and held it in 13 quarters. The position peaked at $869K in Q3 2021. 299 funds tracked by Wall St. Rank hold GH as of Q2 2023.

  • Northeast Financial Consultants reported no remaining Guardant Health position as of Q2 2023 after selling out during the quarter.
  • Northeast Financial Consultants sold 8,646 Guardant Health shares in Q2 2023, an estimated $203K.
  • Northeast Financial Consultants first reported a position in Guardant Health in Q1 2020 and held it in 13 quarters.
  • Northeast Financial Consultants's Guardant Health position peaked at $869K in Q3 2021.
  • 299 funds tracked by Wall St. Rank held Guardant Health as of Q2 2023.

Based on Northeast Financial Consultants's 13F filing for Q2 2023, filed 8 Aug 2023.